PHILADELPHIA, PA — Proscia was recognized in the 2026 MedTech Breakthrough Awards as pharmaceutical companies increasingly adopt artificial intelligence and digital pathology tools to accelerate biomarker research and precision medicine development.

The company received its second consecutive MedTech Breakthrough Award for technology designed to integrate pathology data into drug development and clinical trial matching workflows, Proscia announced.

Proscia stated that its Concentriq platform now connects 16 of the world’s 20 largest pharmaceutical companies alongside a laboratory network expected to generate roughly 8 million diagnoses annually.

The company’s Aperture platform applies AI to pathology images alongside biomarker, molecular, and clinical data to help drug developers identify patients, support companion diagnostic programs, and generate evidence for precision therapies.

The recognition highlights growing industry investment in digital pathology infrastructure as drugmakers seek earlier access to clinically relevant tissue data during therapeutic development.

Chief Strategy Officer Nathan Buchbinder said pathology data has historically remained fragmented and underused despite its potential value in identifying disease characteristics and treatment candidates.

“Pathology data captures a rich biological signal that is often siloed and used retrospectively,” Buchbinder said. “This award reflects Proscia’s role in enabling pharmaceutical companies to harness these insights as drug programs demand an incredibly nuanced understanding of disease and early access to qualified candidates.”

MedTech Breakthrough Managing Director Steve Johansson stated that Proscia was recognized for addressing what he described as a significant gap in precision medicine through broader clinical integration of pathology intelligence.

The MedTech Breakthrough Awards program, now in its 10th year, received submissions from companies in more than 20 countries, according to the organization.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.